Company profile for Precision BioSciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Precision BioSciences is a publicly held biotechnology company dedicated to improving life through its next generation gene editing technology, ARCUS. Precision’s cell therapy, gene therapy, and agriculture programs are based on the proprietary ARCUS gene editing platform, which features coordinated target site binding and DNA cutting to ensure precise edits. Our team includes pioneers in genome engineering, biotech business...
Precision BioSciences is a publicly held biotechnology company dedicated to improving life through its next generation gene editing technology, ARCUS. Precision’s cell therapy, gene therapy, and agriculture programs are based on the proprietary ARCUS gene editing platform, which features coordinated target site binding and DNA cutting to ensure precise edits. Our team includes pioneers in genome engineering, biotech business leaders, and a growing staff of committed Precisioneers.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
302 East Pettigrew St. Dibrell Building Suite A-100 Durham, NC 27701
Telephone
Telephone
919.314.5512
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251119821874/en/Precision-BioSciences-Announces-Presentation-of-Clinical-Data-from-the-ELIMINATE-B-Trial-at-HEP-DART-2025

BUSINESSWIRE
19 Nov 2025

https://www.businesswire.com/news/home/20251110273856/en/Precision-BioSciences-Presents-Late-Breaking-Phase-1-PBGENE-HBV-Data-at-AASLD-The-Liver-Meeting-Showing-Safety-Tolerability-and-Cumulative-Dose-Dependent-Antiviral-Activity-in-First-Three-Cohorts

BUSINESS WIRE
10 Nov 2025

https://www.businesswire.com/news/home/20251110811186/en/Precision-BioSciences-Announces-%2475-Million-Offering-of-Common-Stock-Pre-Funded-Warrants-and-Warrants

BUSINESSWIRE
10 Nov 2025

https://www.businesswire.com/news/home/20251103301442/en/Precision-BioSciences-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Business-Update

BUSINESSWIRE
03 Nov 2025

https://www.businesswire.com/news/home/20251031483791/en/Precision-BioSciences-to-Report-Third-Quarter-2025-Financial-Results-on-November-3-2025

BUSINESSWIRE
31 Oct 2025

https://www.pharmiweb.com/press-release/2025-10-14/precision-biosciences-announces-late-breaking-oral-presentation-for-pbgene-hbv-at-aasld-the-liver-me

PHARMIWEB
14 Oct 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty